The Medical Letter®

on Drugs and Therapeutics

Volume 59 April 24, 2017

1519

In Brief: New Adult Immunization Recommendations......p 70

Important Copyright Message

FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: Subscriptions, Site Licenses, Reprints or call customer service at: 800-211-2769

The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call: 800-211-2769

The Medical Letter®

on Drugs and Therapeutics

Volume 59 (Issue 1519) April 24, 2017

Take CME Exams

IN BRIEF

New Adult Immunization Recommendations

The 2017 adult immunization schedule approved by the CDC's Advisory Committee on Immunization Practices (ACIP) includes some new or revised recommendations.1 The complete schedule is available on the CDC's website (www.cdc.gov/vaccines/schedules). New recommendations for use of influenza vaccine during the 2016-2017 season were included in a previous issue of The Medical Letter.2 Updated recommendations for other vaccines are summarized below. Recommendations for routine use of vaccines in adults were reviewed in an earlier issue.3

Human Papillomavirus Vaccine (HPV: Gardasil, Gardasil 9)4

Update: Dosing schedules for young adults who did not complete an HPV vaccine series as adolescents

- ▶ Previously unvaccinated adult females ≤26 years old and males ≤21 years old should receive a 3-dose series (0, 1-2, and 6 months). Males 22-26 years old who have immunocompromising conditions (including HIV infection) and those who have sex with men should also receive a 3-dose series.
- ▶ All of those above who received 2 doses ≥5 months apart before age 15 do not need an additional dose.
- ▶ All of those above who received only 1 dose or 2 doses <5 months apart before age 15 should receive 1 additional dose.

Hepatitis B Vaccine

(Hep B: Engerix-B, Recombivax HB; HepA/HepB: Twinrix)

Update: List of chronic liver disease conditions for which Hep B vaccine is recommended

Adults with chronic liver disease including, but not limited to, hepatitis C virus infection, cirrhosis, fatty liver disease, alcoholic liver disease, autoimmune hepatitis, and an ALT or AST level >2 times the upper limit of normal should receive a 3-dose series (0, 1, and 6 months).

Meningococcal Conjugate Vaccine Serogroups A, C, W, and Y (MenACWY: Menactra, Menveo)

Update: MenACWY vaccine is recommended for all adults with HIV infection

- Previously unvaccinated adults with HIV infection should receive 2 doses ≥2 months apart and should be revaccinated every 5 years.
- Adults with HIV infection who previously received 1 dose should receive a second dose \geq 2 months after the first.

Meningococcal Vaccine Serogroup B (MenB-FHbp: Trumenba; MenB-4C: Bexsero)5,6

Update: Dosing schedule for Trumenba

- Adults who are at increased risk for meningococcal disease (anatomical or functional asplenia, persistent complement component deficiencies, microbiologists routinely exposed to isolates of Neisseria meningitidis) and those who are vaccinated during serogroup B disease outbreaks should receive a 3-dose series (0, 1-2, and 6 months) of Trumenba. (2 doses of Bexsero ≥1 month apart can be given instead.)
- Young adults 16 through 23 years old (preferably at 16-18 years of age) who are healthy and not at increased risk for meningococcal disease may receive a 2-dose series (0 and 6 months) of Trumenba. (2 doses of Bexsero ≥1 month apart may be given instead.)

- DK Kim et al. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older United States, 2017. MMWR Morb Mortal Wkly Rep 2017; 66:136.
 Influenza vaccine for 2016-2017. Med Lett Drugs Ther 2016; 58:127.
 Adult immunization. Treat Guidel Med Lett 2014; 12:39.

- Gardasil 9 a broader HPV vaccine. Med Lett Drugs Ther 2015; 57:47. Trumenba: a serogroup B meningococcal vaccine. Med Lett Drugs Ther 2015; 57:5.
- Bexsero a second serogroup B meningococcal vaccine. Med Lett Drugs Ther 2015; 57:158.

Follow us on Twitter 😈 Like us on Facebook 📑



PRESIDENT: Mark Abramowicz, M.D.; VICE PRESIDENT AND EXECUTIVE EDITOR: Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School; EDITOR IN CHIEF: Jean-Marie Pflomm, Pharm.D.; ASSOCIATE EDITORS: Susan M. Daron, Pharm.D., Amy Faucard, MLS, Corinne Z. Morrison, Pharm.D., Michael P. Viscusi, Pharm.D.; CONSULTING EDITORS: Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

CONTRIBUTING EDITORS: Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University Health; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Franco M. Muggia, M.D., New York University Medical Center; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; F. Estelle R. Simons, M.D., University of Manitoba; Neal H. Steigbigel, M.D., New York University School of Medicine; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

MANAGING EDITOR: Susie Wong; ASSISTANT MANAGING EDITOR: Liz Donohue; EDITORIAL ASSISTANT: Cheryl Brown

FULFILLMENT AND SYSTEMS MANAGER: Cristine Romatowski; SITE LICENSE SALES: Elaine Reaney-Tomaselli; EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS: Joanne F. Valentino; VICE PRESIDENT AND PUBLISHER: Yosef Wissner-Levy

Founded in 1959 by

Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer. The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

Address:

The Medical Letter, Inc. 145 Huguenot St. Ste. 312 New Rochelle, NY 10801-7537 **Customer Service:** Call: 800-211-2769 or 914-235-0500 Fax: 914-632-1733

E-mail: custserv@medicalletter.org

Subscription Services

Permissions: To reproduce any portion of this issue, please e-mail your request to: permissions@medicalletter.org

Subscriptions (US): 1 year - \$159; 2 years - \$298; 3 years - \$398. \$65 per year for students, interns, residents, and fellows in the US and Canada. Reprints - \$12 each. Site License Inquiries: E-mail: SubQuote@medicalletter.org Call: 800-211-2769 Special rates available for bulk subscriptions.

Get Connected:



Copyright 2017, ISSN 1523-2859

